Tharimmune issues comprehensive corporate update including lead th104 as critical national security solution against weaponized fentanyl and th023 poised to revolutionize oral antibody delivery

-company closes approximately $5.47 million in equity financing in 2q/3q25 -th104 potentially fills a critical national security need against weaponized fentanyl - th023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation -company strengthens operational leadership, corporate governance and accounting red bank, nj / access newswire / august 4, 2025 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today issued a comprehensive corporate update highlighting significant advancements across its pipeline. the update underscores the rapid progression of th104 as a lead asset addressing critical national security risks posed by weaponized fentanyl, and the transformative potential of th023 in pioneering oral antibody delivery for widespread inflammatory conditions.
THAR Ratings Summary
THAR Quant Ranking